Results 71 to 80 of about 138,725 (257)

JAK Inhibitors and Oxidative Stress Control [PDF]

Frontiers in Immunology, 2019
Primary Sjögren's syndrome (SjS) is a complex autoimmune epithelitis, with few treatment options, but the use of Janus kinase (JAK) inhibitors is promising because suppression of the JAK/signal transducer and activator of transcription (STAT) pathway improves sicca manifestations.
Amandine Charras, Pinelopi Arvaniti, Pinelopi Arvaniti, Pinelopi Arvaniti, Christelle Le Dantec, George N. Dalekos, George N. Dalekos, Kaliopi Zachou, Kaliopi Zachou, Anne Bordron, Yves Renaudineau, Yves Renaudineau   +11 more
openaire   +4 more sources

Research progress on tofacitinib in the treatment of chronic actinic dermatitis

Pifu-xingbing zhenliaoxue zazhi
Chronic actinic dermatitis (CAD) is a group of immune-mediated diseases characterized by photosensitivity. Tofacitinib, a Janus kinase (JAK) 1/3 inhibitor, is currently the most extensively reported and widely used JAK inhibitor for the treatment of CAD.
WU Hui, SHEN Haojia, HE Zezhi, CHEN Jiaoquan, LI Runxiang, ZHU Huilan   +5 more
doaj   +1 more source

Understanding signaling cascades in melanoma [PDF]

, 2008
Understanding regulatory pathways involved in melanoma development and progression has advanced significantly in recent years. It is now appreciated that melanoma is the result of complex changes in multiple signaling pathways that affect growth control,
Akslen L. A., Berger A. J., Berking C., Bhoumik A., Bhoumik A., Chen X., Claffey K. P., Collisson E. A., Coppock D. L., Dahia P. L. M., Dhawan P., Dorsky R. I., Ehebauer M., Eisenmann K. M., Genersch E., Goding C. R., Goodall J., Gorden A., Guldberg P., Gurzov E. N., Herbst R. A., Hingorani S. R., Hughes M. J., Huguier S., Iozzo R. V., Jonsson M., Jorgensen K., Karin M., Kennedy N. J., Kumar R., Lacal P. M., Li N., Maeno K., Meyskens F. L., Miller J. R., Miyazono K., Niu G., Okuyama R., Omholt K., Park B. K., Piek E., Qin J.-Z., Rangaswami H., Rimm D. L., Rofstad E. K., Satyamoorthy K., Soldatencov V. A., Stewart F. A., Tago K.-i., Thomson J. A., Tokita T., Tsai E. Y., Tsao H., van Elsas A., Wu M., Yang J., Yang J., Yang Y. M., Zhou X. P.   +58 more
core   +1 more source

Potential role of upadacitinib in cytomegalovirus colitis recurrence

European Journal of Case Reports in Internal Medicine
Background: Cytomegalovirus (CMV) colitis is a common complication in patients with ulcerative colitis (UC), which is often associated with immunosuppressive therapies including steroids, azathioprine, and biologics such as infliximab.
Kaito Tsujinaka, Marina Kannno, Atsushi Ogawa, Kei Kawada, Mitsuhiro Goda, Hisanori Uehara, Keisuke Ishizawa   +6 more
doaj   +1 more source

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

BMC Rheumatology, 2018
Background Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.
Julie M. Parmentier, Jeff Voss, Candace Graff, Annette Schwartz, Maria Argiriadi, Michael Friedman, Heidi S. Camp, Robert J. Padley, Jonathan S. George, Deborah Hyland, Matthew Rosebraugh, Neil Wishart, Lisa Olson, Andrew J. Long   +13 more
doaj   +1 more source

Treatment of Atopic Dermatitis Using JAK Inhibitors: A Systematic Review

European Medical Journal Dermatology, 2019
Background: The advent of JAK inhibitors (JAKi) has significantly modernised the treatment of atopic dermatitis (AD), offering a novel approach to treating this recalcitrant dermatological condition.
Stefan Siedlikowski, Vijay Sandhu, Charles Lynde   +2 more
doaj  

Immunotargets and Therapy for Prurigo Nodularis

ImmunoTargets and Therapy, 2022
Angelina Labib, Teresa Ju, Ashley Vander Does, Gil Yosipovitch Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence: Gil Yosipovitch, Dr ...
Labib A, Ju T, Vander Does A, Yosipovitch G   +3 more
doaj  

LNK suppresses interferon signaling in melanoma. [PDF]

, 2019
LNK (SH2B3) is a key negative regulator of JAK-STAT signaling which has been extensively studied in malignant hematopoietic diseases. We found that LNK is significantly elevated in cutaneous melanoma; this elevation is correlated with hyperactive ...
Ding, Ling-Wen, Doan, Ngan, Edwards, Jarem J, Fernández, Lucia Torres, Koeffler, H Phillip, Lin, De-Chen, Loh, Xin-Yi, Mullins, David W, Pein, Maren, Ran, Xue-Bin, Said, Jonathan W, Scolyer, Richard A, Sun, Qiao-Yang, Thompson, John F, Venkatachalam, Nachiyappan, Wilmott, James S, Xiao, Jin-Fen, Xu, Liang, Yang, Henry, Zhou, Si-Qin   +19 more
core  

Computational models for inferring biochemical networks [PDF]

, 2014
Biochemical networks are of great practical importance. The interaction of biological compounds in cells has been enforced to a proper understanding by the numerous bioinformatics projects, which contributed to a vast amount of biological information ...
Crina Grosan, D Voet, David Gilbert, E Aarts, G Fogel, I Swameye, J Kitagawa, JT Heaton, K Yeung, K Yeung, M Heiner, M Oltean, M Oltean, Ovidiu Parvu, R Breitling, Ramona Stoica, S Kirkpatrick, Silvia Rausanu, U Klingmueller, W Elliot, Zujian Wu   +20 more
core   +1 more source

Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy [PDF]

, 2022
Andrea Amstad, Eleftherios Papagiannoulis, Almut Scherer, Andrea Rubbert‐Roth, Axel Finckh, Ruediger B. Müeller, Jean Dudler, Burkhard Möller, Peter M. Villiger, Martin M P Schulz, Diego Kyburz   +10 more
openalex   +1 more source